Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954 is registered in ClinicalTrials.gov with IDEAYA Biosciences as lead sponsor.

NCT NCT05907954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05907954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Lead sponsor
IDEAYA Biosciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 3, 2023
Completion date
April 30, 2030
Enrollment
160 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma